Life Sciences

Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
16 June 2021

Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code the molecular interactions in the gut microbiome impacting...

Read the press release
Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression
15 June 2021

Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression

Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for...

Read the press release
Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors
24 March 2021

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors

Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021

ENTEROME SA, a clinical stage biopharmaceutical...

Read the press release
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
17 March 2021

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population...

Read the press release
Health for Life Capital Fund, managed by Seventure Partners, increases focus on skin microbiome in its portfolio
11 January 2021

Health for Life Capital Fund, managed by Seventure Partners, increases focus on skin microbiome in its portfolio

Seventure Partners, one of Europe’s leaders in financing innovation and a world leader in life science microbiome investment, has increased focus on skin microbiome...

Read the press release
Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on europeanpharmaceuticalreview.com
16 December 2020

Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on europeanpharmaceuticalreview.com

Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases by Hervé Affagard (Maat Pharma) published on...

Read more
MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic
12 November 2020

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT Pharma announced today that it treated its first patient in a Phase 1 clinical trial to evaluate the safety and tolerability of MaaT033, a capsule formulation of the...

Read more
DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions
9 November 2020

DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions

A consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million...

Read more
BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD
3 November 2020

BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the...

Read more